Transkaryotic Therapies Seeks Amgen Patent Dismissal
Transkaryotic Therapies and its partner Hoechst Marion Roussel haveasked the US District Court in Boston to dismiss a patent infringement action filed by Amgen in April relating to erythropoietin. Since 1994, TKT and HMR have collaborated on the development of Gene-Activated erythropoietin for the treatment of anemia. "Neither TKT's pioneering Gene Activation technology nor GA-EPO, a truly human erythropoietin, infringe any Amgen patents," said Richard Markham, chief executive of HMR.
HMR has filed an Investigational New Drug application with the US Food and Drug Administration to commence Phase I trials of GA-EPO for the treatment of anemia. The submission results in a $2 million milestone payment to TKT from HMR.
Amgen's share price fell (see page 8) on worries about competition from TKT in trading of more than 4 million shares, as compared to the usual 2.6 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze